Study of deuruxolitinib for teens with severe alopecia areata
Part of Skin clinical trials.
This study tests an investigational oral medication (deuruxolitinib) for adolescents with severe alopecia areata (hair loss). It aims to see if it can help hair regrow safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 18 years old.
- You have had alopecia areata for at least 6 months but not more than 10 years.
- You have lost at least half of your scalp hair (50% or more).
- You are willing to follow the study schedule and requirements.
- You do not have other scalp conditions (like psoriasis or severe dandruff) that need treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.
This study tests two different doses of a pill called ritlecitinib to see if it can help regrow hair in people with significant hair loss from alopecia areata. It is for people aged 12 and older who have lost at least half of their scalp hair.
This study follows people with alopecia areata who are starting treatment with ritlecitinib (a medication). It looks at how well the treatment works in real life and how it affects your symptoms and quality of life.
This study tests whether a new drug called deuruxolitinib can help regrow hair in people with alopecia areata (an autoimmune condition causing patchy hair loss). The drug works by blocking certain immune signals that attack hair follicles.
This trial tests an oral medication called NXC-736 for people with moderate to severe alopecia areata. It aims to see if the drug is safe and can help regrow hair.
This trial tests an experimental tablet for teenagers with severe alopecia areata, a condition causing patchy hair loss. The treatment may help regrow hair with clearer information about safety and effectiveness.
Hear when a new Alopecia Areata trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.